NeoDeck Holdings Corp. – Trademark Portfolio
Entity Type: 03
NeoDeck Holdings Corp. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 11 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include RX, NEOMED RX, CLINICALVAULT, PATIENT VAULT, and PV PATIENT VAULT. The owner is based in Ponce, PR.
2053 Ponce By Pass Suite 209
Ponce, PR 00717
Showing of trademarks Trademarks
Trademark Classifications
NeoDeck Holdings Corp.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does NeoDeck Holdings Corp. have?
NeoDeck Holdings Corp. has 14 U.S. trademarks filed with the USPTO. Of these, 8 registered, 3 abandoned, 3 cancelled.
What trademark classes does NeoDeck Holdings Corp. file in?
NeoDeck Holdings Corp. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are NeoDeck Holdings Corp.'s most well-known trademarks?
NeoDeck Holdings Corp.'s registered trademark portfolio includes well-known marks such as RX, NEOMED RX, CLINICALVAULT, PATIENT VAULT, and PV PATIENT VAULT. These are among 8 currently registered trademarks in the portfolio.
What is NeoDeck Holdings Corp.'s trademark registration success rate?
NeoDeck Holdings Corp. has a 57% trademark registration rate, with 8 out of 14 resolved applications resulting in successful registration. Currently, 0 applications are pending review.